Editorial

Measles Deaths in England Expose the Cost of Missed Protection

Europe’s AMR Strategy Depends on the Lab Result Being Right

Heatwaves are emerging as a cardiovascular risk factor, prompting calls for stronger climate adaptation and public health policies

Eli Lilly’s retatrutide could reset obesity care, but rising demand and grey-market access are testing regulators and health systems

Metabolic health is no longer just a clinic problem. It is a city, climate and equity problem

Can AstraZeneca challenge the obesity market leaders? New GLP-1 data signal growing ambitions beyond oncology

AMR Stewardship Starts Before the Antibiotic Is Prescribed

HEARTS 2.0: Latin America moves beyond hypertension and into cardio-kidney-metabolic care

GIST Care Looks Beyond First-Generation KIT Control
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
